Uptravi Added to Lower Cost Treatment List for PAH Patients in Australia

Uptravi Added to Lower Cost Treatment List for PAH Patients in Australia

286260

Uptravi Added to Lower Cost Treatment List for PAH Patients in Australia

Australia’s government has taken a step to ensure that Uptravi (selexipag), an oral therapy for pulmonary arterial hypertension (PAH), is available to people affected by the disease. Janssen’s treatment is now included in the country’s Pharmaceutical Benefits Scheme (PBS) listing, meaning it is available to residents in this program at a subsidized cost. The co-pay for most patients getting a prescription medicine through the PBS is currently set at a maximum of AU$41.30 (about $32). Retirees, veterans…

You must be logged in to read/download the full post.